MedPath

Ketoconazole

Generic Name
Ketoconazole
Brand Names
Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
Drug Type
Small Molecule
Chemical Formula
C26H28Cl2N4O4
CAS Number
65277-42-1
Unique Ingredient Identifier
R9400W927I
Background

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, miconazole and clotrimazole, due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis. These effects combined with waning efficacy led to its eventual replacement by triazole agents, fluconazole, itraconazole, voriconazole, and posaconazole. Ketoconazole and its predecessor clotrimazole continue to be used in topical formulations.

Indication

Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.

Associated Conditions
Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection

Study Evaluating The Safety And Tolerability Of Administration Of Single Oral Doses Of SAM-760 To Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo of SAM-760
First Posted Date
2009-07-29
Last Posted Date
2013-02-25
Lead Sponsor
Pfizer
Target Recruit Count
124
Registration Number
NCT00948662
Locations
🇫🇷

Pfizer Investigational Site, Rueil Malmaison, France

A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Pharmacokinetics
Drug Interactions
First Posted Date
2009-06-08
Last Posted Date
2010-04-30
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
14
Registration Number
NCT00915746

Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2009-05-08
Last Posted Date
2017-03-30
Lead Sponsor
University of California, Davis
Target Recruit Count
30
Registration Number
NCT00895310
Locations
🇺🇸

University of California, Davis Cancer Center, Sacramento, California, United States

Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study

Not Applicable
Conditions
Prostate Cancer
Interventions
First Posted Date
2009-03-27
Last Posted Date
2009-03-27
Lead Sponsor
Kansas City Veteran Affairs Medical Center
Target Recruit Count
20
Registration Number
NCT00870714
Locations
🇺🇸

Kansas City VAMC, Kansas City, Missouri, United States

Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo + GW642444M
First Posted Date
2009-03-20
Last Posted Date
2017-07-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
20
Registration Number
NCT00866515
Locations
🇦🇺

GSK Investigational Site, Randwick, New South Wales, Australia

Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis

First Posted Date
2009-03-17
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
326
Registration Number
NCT00862654
Locations
🇲🇽

Galderma Investigational Center, Zapopan, Jalisco, Mexico

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

First Posted Date
2009-03-12
Last Posted Date
2011-01-25
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
30
Registration Number
NCT00860275
Locations
🇺🇸

Ppd Development, Lp, Austin, Texas, United States

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Prostate Cancer
Interventions
First Posted Date
2009-03-11
Last Posted Date
2025-04-30
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
55
Registration Number
NCT00859781
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

🇺🇸

The University of Kansas Cancer Center, Westwood, Kansas, United States

🇺🇸

USC/Norris Comprehensive cancer center, Los Angeles, California, United States

and more 6 locations

Ketoconazole Foam 2% for the Treatment of Versicolor

Phase 4
Completed
Conditions
Tinea Versicolor
Interventions
First Posted Date
2009-01-27
Last Posted Date
2012-08-22
Lead Sponsor
Boni Elewski, MD
Target Recruit Count
11
Registration Number
NCT00830388
Locations
🇺🇸

UAB Dermatology, Birmingham, Alabama, United States

Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis

Phase 4
Completed
Conditions
Pityrosporum Folliculitis
Interventions
First Posted Date
2009-01-19
Last Posted Date
2014-08-21
Lead Sponsor
Wayne Fujita, M.D.
Target Recruit Count
10
Registration Number
NCT00824863
Locations
🇺🇸

Aiea Medical Building; Suite 401, Aiea, Hawaii, United States

© Copyright 2025. All Rights Reserved by MedPath